Sana Biotechnology (SANA) Projected to Release Quarterly Earnings on Monday

Sana Biotechnology (NASDAQ:SANA) is anticipated to announce its Q2 2026 results after the market closes on Monday, August 10th. Analysts expect Sana Biotechnology to announce earnings of ($0.1469) per share for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. On average, analysts expect Sana Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sana Biotechnology Trading Down 1.5%

Shares of SANA opened at $3.08 on Monday. Sana Biotechnology has a 12-month low of $2.61 and a 12-month high of $6.55. The company has a market cap of $858.25 million, a PE ratio of -3.31 and a beta of 2.13. The stock has a 50-day moving average price of $3.27 and a 200-day moving average price of $3.53.

Institutional Trading of Sana Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of SANA. Vanguard Group Inc. boosted its stake in shares of Sana Biotechnology by 19.9% during the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock valued at $32,408,000 after purchasing an additional 1,517,474 shares during the period. State Street Corp boosted its position in Sana Biotechnology by 20.6% during the 4th quarter. State Street Corp now owns 8,054,841 shares of the company’s stock valued at $32,783,000 after buying an additional 1,374,300 shares during the period. Geode Capital Management LLC grew its holdings in Sana Biotechnology by 20.3% in the 4th quarter. Geode Capital Management LLC now owns 4,118,138 shares of the company’s stock worth $16,763,000 after acquiring an additional 694,606 shares during the last quarter. Integral Health Asset Management LLC raised its stake in shares of Sana Biotechnology by 50.0% during the fourth quarter. Integral Health Asset Management LLC now owns 3,000,000 shares of the company’s stock valued at $12,210,000 after acquiring an additional 1,000,000 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Sana Biotechnology by 180.8% during the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock worth $7,581,000 after purchasing an additional 1,375,029 shares during the period. Institutional investors own 88.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on SANA. Weiss Ratings raised Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. Rodman & Renshaw assumed coverage on Sana Biotechnology in a research note on Monday, May 11th. They issued a “buy” rating and a $16.00 target price for the company. Wedbush increased their price target on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Finally, Wall Street Zen downgraded shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $9.50.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.